Proceeds will support the continued development of what the company describes as its first-in-class and best-in-class transcriptional enhanced associate domain autopalmitoylation (TEAD) inhibitor, ...

SpringWorks is also evaluating its investigational, oral, selective pan-TEAD inhibitor, SW-682, in a phase I study for treating patients with Hippo-mutant solid tumors. The continued demand for ...

The pan-TEAD inhibitor is one of a number of small molecules specially designed with novel structures using Insilico’s generative AI platform, Pharma.AI.

an FAK inhibitor addition to avutometinib augmented tumor regression with stronger inhibition of MAPK, PI3K and YAP/TEAD signaling than either agent alone The combination of avutometinib ...

Using in silico molecular modelling his group developed a novel pharmacological YAP-TEAD inhibitor that represents a lead compound for the development of new anti-mitogenic therapies. Current research ...